- Home
- MGIH vs MIRA Comparison
MGIH vs MIRA Comparison
Compare MGIH & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- MIRA
- Stock Information
- Founded
- MGIH 1978
- MIRA 2020
- Country
- MGIH Hong Kong
- MIRA United States
- Employees
- MGIH N/A
- MIRA N/A
- Industry
- MGIH Publishing
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- MIRA Health Care
- Exchange
- MGIH Nasdaq
- MIRA Nasdaq
- Market Cap
- MGIH 20.1M
- MIRA 17.4M
- IPO Year
- MGIH 2023
- MIRA 2023
- Fundamental
- Price
- MGIH $1.82
- MIRA $1.21
- Analyst Decision
- MGIH
- MIRA Strong Buy
- Analyst Count
- MGIH 0
- MIRA 2
- Target Price
- MGIH N/A
- MIRA $14.00
- AVG Volume (30 Days)
- MGIH 5.0M
- MIRA 474.3K
- Earning Date
- MGIH 10-30-2024
- MIRA 11-12-2024
- Dividend Yield
- MGIH N/A
- MIRA N/A
- EPS Growth
- MGIH N/A
- MIRA N/A
- EPS
- MGIH N/A
- MIRA N/A
- Revenue
- MGIH $38,530,773.00
- MIRA N/A
- Revenue This Year
- MGIH N/A
- MIRA N/A
- Revenue Next Year
- MGIH N/A
- MIRA N/A
- P/E Ratio
- MGIH N/A
- MIRA N/A
- Revenue Growth
- MGIH N/A
- MIRA N/A
- 52 Week Low
- MGIH $0.98
- MIRA $0.51
- 52 Week High
- MGIH $9.57
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- MGIH 51.48
- MIRA 49.18
- Support Level
- MGIH $1.54
- MIRA $1.13
- Resistance Level
- MGIH $2.87
- MIRA $1.50
- Average True Range (ATR)
- MGIH 0.43
- MIRA 0.11
- MACD
- MGIH 0.00
- MIRA 0.01
- Stochastic Oscillator
- MGIH 22.79
- MIRA 29.27
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.